The Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) exhibits an implied analyst target price of $92.46, indicating a 9.56% potential upside from its current trading price of $84.39, based on the weighted average 12-month forward targets of its underlying holdings. This projected growth is significantly influenced by key constituents such as Stoke Therapeutics (STOK), with a 28.54% upside to its analyst target, Healthcare Services Group (HCSG) showing 13.02% upside, and Wayfair (W) with an 11.41% upside, according to analyst consensus.
The Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) currently trades near $84.39 per unit, with an implied analyst 12-month target price of $92.46, suggesting a 9.56% potential upside. This projection is derived from the weighted average of analyst target prices for JSMD's underlying holdings, reflecting a mildly positive sentiment on the ETF's near-term prospects. Significant contributors to this projected upside include Stoke Therapeutics Inc (STOK), which analysts anticipate could rise 28.54% from $22.82 to $29.33 per share. Healthcare Services Group, Inc. (HCSG) also shows a 13.02% upside from $17.99 to $20.33, while Wayfair Inc (W) is projected to increase 11.41% from $100.86 to $112.37. These individual stock targets underpin the overall positive outlook for the JSMD ETF. However, the analysis carries an "uncertain" tone, questioning the justification and timeliness of these analyst targets. The article highlights that high price targets could reflect optimism or be outdated, potentially leading to future downgrades. This suggests that while the quantitative upside is present, qualitative factors and recent developments require deeper scrutiny.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
